Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL

Naval Daver; Marina Konopleva

doi:10.1182/blood-2016-07-724948

Cotargeting BCL-2 and BCL-X_L for maximal efficacy in ALL

Naval Daver, Marina Konopleva

Leukemia

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

In this issue of Blood, Khaw et al show that in contrast to the impressive antileukemic activity achieved by sole BCL-2 inhibition in chronic lymphocytic leukemia (CLL), optimal antileukemic activity in pediatric acute lymphoblastic leukemia (ALL) xenografts required concurrent inhibition of both BCL-2 and BCL-X_L.¹.

Original language	English (US)
Pages (from-to)	1316-1317
Number of pages	2
Journal	Blood
Volume	128
Issue number	10
DOIs	https://doi.org/10.1182/blood-2016-07-724948
State	Published - Sep 8 2016

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2016-07-724948

Cite this

@article{a38397162f634c3d9286646d9b23193e,

title = "Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL",

abstract = "In this issue of Blood, Khaw et al show that in contrast to the impressive antileukemic activity achieved by sole BCL-2 inhibition in chronic lymphocytic leukemia (CLL), optimal antileukemic activity in pediatric acute lymphoblastic leukemia (ALL) xenografts required concurrent inhibition of both BCL-2 and BCL-XL.1.",

author = "Naval Daver and Marina Konopleva",

note = "Publisher Copyright: {\textcopyright} 2016 by The American Society of Hematology.",

year = "2016",

month = sep,

day = "8",

doi = "10.1182/blood-2016-07-724948",

language = "English (US)",

volume = "128",

pages = "1316--1317",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "10",

}

TY - JOUR

T1 - Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL

AU - Daver, Naval

AU - Konopleva, Marina

PY - 2016/9/8

Y1 - 2016/9/8

N2 - In this issue of Blood, Khaw et al show that in contrast to the impressive antileukemic activity achieved by sole BCL-2 inhibition in chronic lymphocytic leukemia (CLL), optimal antileukemic activity in pediatric acute lymphoblastic leukemia (ALL) xenografts required concurrent inhibition of both BCL-2 and BCL-XL.1.

AB - In this issue of Blood, Khaw et al show that in contrast to the impressive antileukemic activity achieved by sole BCL-2 inhibition in chronic lymphocytic leukemia (CLL), optimal antileukemic activity in pediatric acute lymphoblastic leukemia (ALL) xenografts required concurrent inhibition of both BCL-2 and BCL-XL.1.

UR - http://www.scopus.com/inward/record.url?scp=84987794621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987794621&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-07-724948

DO - 10.1182/blood-2016-07-724948

M3 - Comment/debate

C2 - 27609539

AN - SCOPUS:84987794621

SN - 0006-4971

VL - 128

SP - 1316

EP - 1317

JO - Blood

JF - Blood

IS - 10

ER -

Cotargeting BCL-2 and BCL-X_L for maximal efficacy in ALL

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this